Angarus Therapeutics Overview
- Founded
- 2018
- Status
- Private
- Latest Deal Type
- Seed
- Investors
- 1
Angarus Therapeutics General Information
Description
Developer of immuno-oncology therapies intended to respond to the urgent needs of cancer treatment. The company is engaged in developing checkpoint blockers on the innate immunity STING pathway, with a preclinical data demonstrating that a combination of checkpoint blockers, both innate and adaptive, leads to long term survival, thereby providing patients with wide-range of cancer type treatments.
Contact Information
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 428 Oakmead Parkway
- Sunnyvale, CA 94085
- United States
Angarus Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Seed Round | 15-May-2020 | Completed | Pre-Clinical Trials |
Angarus Therapeutics Executive Team (4)
Angarus Therapeutics Board Members (1)
| Name | Representing | Role | Since |
|---|---|---|---|
| Chih-Ping Liu Ph.D | Angarus Therapeutics | Co-Founder, Managing Director and Executive Chairman of the Board of Directors | 000 0000 |
Angarus Therapeutics Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Tsingyuan Ventures | Venture Capital | Minority | 000 0000 | 000000 0 |